

## Response letter

September 12th, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 18931-Revised manuscript.docx).

**Title:** Personalized medicine in gastric cancer: Where are we and where are we going?

**Authors:** Alexandre A. Jácome, Anelisa K. Coutinho, Enaldo M. Lima, Aline C. Andrade, José Sebastião dos Santos.

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 18931

We are grateful with the comments and suggestions raised by the reviewers, which, certainly, improved the quality of our paper. Below, we explain all the suggestions and corrections that have been made:

1. Reviewer 00001832: The reviewer suggests adding some comments related to adjuvant therapy of gastric cancer, and its different modalities. Adjuvant therapy is beyond the scope of the present paper. Recently we published a review article at *World Journal of Gastroenterology* discussing the different approaches of adjuvant therapy. The present paper discusses the personalized treatment in gastric cancer, and, there are no studies with available results evaluating tailored therapies in adjuvant therapy. In relation to add the information of negative or positive trial, we opted to not inform, because the trials had different primary and

secondary end-points, some are phase II or phase III, so that, these informations could misunderstand the readers. We agree with the suggestion of the concept of driver mutation, and we modified in the text.

2. Reviewer 03017210: No suggestions.
3. Reviewer 00253956: No suggestions.
4. Reviewer 03016888:
  1. In page 9, line 6-9, there is information comparing Eastern and Western patients as commented in TCGA study, which is the reference already previously cited.
  2. The concept of driver mutation was reviewed and modified in the text, as also suggested by the first reviewer.
  3. The suggestion was accepted and incorporated in the text.
  4. The suggestion was accepted and we excluded the sentences which we discussed the comparison between REGARD and RAINBOW studies.
  5. The suggestion was accepted and Shine study was included.
  6. The suggestions were accepted. Clinical trials with onartuzumab and RILOMET-1 and MEGA trials were also included.
  7. The suggestions were accepted. Study with PARP inhibitor was included. We opted to not include the study evaluating BBI-608 because the study has a heterogeneous population, which includes patients with several malignancies, not only gastric cancer.
  8. We included the citation of "Table 1" in the text.

Thank you for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Alexandre A. A. Jácome, MD, PhD